Login to Your Account

Iteos heading back to clinic with IDO-1 inhibitor after Pfizer hand-back

By Nuala Moran
Staff Writer

Thursday, January 4, 2018

LONDON – Iteos Therapeutics SA is moving to plot a route forward for its lead program, EOS-200271, after Pfizer Inc. cut short a phase I study in glioblastoma and handed back rights to the indoleamine 2,3-dioxygenase (IDO-1) inhibitor.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription